Canada markets close in 5 hours 51 minutes

Alpha Cognition Inc. (ACOGF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.5800+0.0800 (+16.00%)
As of 09:47AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.5000
Open0.5800
BidN/A x N/A
AskN/A x N/A
Day's Range0.5800 - 0.5800
52 Week Range0.4880 - 1.8000
Volume1,000
Avg. Volume5,387
Market Cap40.34M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • Business Wire

    Alpha Cognition Announces Fourth Quarter and Full Year 2021 Results and Company Update

    VANCOUVER, April 28, 2022--Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the fourth quarter and full year ended December 31, 2021.

  • Business Wire

    Alpha Cognition Announces Change of CFO, Grant of Stock Options and Addition to the Board of Directors

    VANCOUVER, British Columbia, April 12, 2022--Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announces the appointment of Don Kalkofen as Chief Financial Officer (CFO) to replace Jeremy Wright. Mr. Wright will continue to assist the Company in a consulting capacity.

  • Business Wire

    Alpha Cognition Announces Positive Data from Pre-Clinical Studies of ALPHA-0602 (Progranulin) for Amyotrophic Lateral Sclerosis (ALS)

    VANCOUVER, British Columbia, March 29, 2022--Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) ("Alpha Cognition" (ACI), or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce positive preclinical data from their ALPHA-0602 ALS gene therapy program. These data underscore the robust preclinical evidence supporting Alpha Cognition’s AAV-based gen